KRAS and neoplasm: Subcutaneous xenograft tumor models were used to confirm the differential activity of RGS in SW48 (RAS wild-type) and DLD1 (KRAS G13D mutation) in vivo, and tumor-bearing nude mice were randomly assigned to receive PBS or RGS.